Journal article
Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort
CS Tam, JN Allan, T Siddiqi, TJ Kipps, R Jacobs, S Opat, PM Barr, A Tedeschi, L Trentin, R Bannerji, S Jackson, BJ Kuss, C Moreno, E Szafer-Glusman, K Russell, C Zhou, J Ninomoto, JP Dean, WG Wierda, P Ghia
Blood | AMER SOC HEMATOLOGY | Published : 2022
Abstract
CAPTIVATE (NCT02910583) is an international phase 2 study in patients aged ≤70 years with previously untreated chronic lymphocytic leukemia (CLL). Results from the cohort investigating fixed-duration (FD) treatment with ibrutinib plus venetoclax are reported. Patients received 3 cycles of ibrutinib lead-in then 12 cycles of ibrutinib plus venetoclax (oral ibrutinib [420 mg/d]; oral venetoclax [5-week ramp-up to 400 mg/d]). The primary endpoint was complete response (CR) rate. Hypothesis testing was performed for patients without del(17p) with prespecified analyses in all treated patients. Secondary endpoints included undetectable minimal residual disease (uMRD) rates, progression-free surviv..
View full abstractGrants
Funding Acknowledgements
The authors thank all the patients who participated in this study and their supportive families, as well as the investigators and clinical research staff from the study centers. The authors also thank Lisa J. Croner for her valuable contributions to bioinformatics analysis of next-generation sequencing data; Lisa J. Croner is an employee of AbbVie and owns AbbVie stock. This study was supported by Pharmacyclics LLC, an AbbVie Company. Medical writing support was provided by Melanie Sweetlove and funded by Pharmacyclics LLC, an AbbVie Company.